KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Hypermethylation of tumor suppressor genes is a hallmark of leukemia. The hypomethylating agent decitabine covalently binds, and degrades DNA (cytosine‐5)‐methyltransferase 1 (DNMT1). Structural similarities within DNA‐binding domains of DNMT1, and the leukemic driver histone‐lysine N‐methyltransfer...
Saved in:
| Main Authors: | Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13792 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting menin for precision therapy in high-risk acute myeloid leukemia
by: Abdur Jamil, et al.
Published: (2025-01-01) -
Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study
by: Zhongli Hu, et al.
Published: (2024-12-01) -
Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies
by: Sara Zehtabcheh, et al.
Published: (2025-05-01) -
Mechanism of action of decitabine in treating acute lymphoblastic leukemia
by: Xiaohui Gao, et al.
Published: (2025-07-01) -
KMT2A-rearranged acute lymphoblastic leukaemia
by: Rishi S. Kotecha, et al.
Published: (2024-12-01)